NCT02742987View on ClinicalTrials.gov

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Coronary Artery DiseaseDiabetes Mellitus
Interventions
DRUG

Ticagrelor

Ticagrelor 90 mg twice daily

DRUG

Clopidogrel

Clopidogrel 150 mg once daily

DRUG

Standard medical therapy

Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

All Listed Sponsors
lead

Campus Bio-Medico University

OTHER

NCT02742987 - Clopidogrel Versus Ticagrelor in Type-2 Diabetes | Biotech Hunter | Biotech Hunter